XML 25 R21.htm IDEA: XBRL DOCUMENT
v3.19.3

Segment Reporting (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2019
Segment Reporting [Abstract] |
Financial Information with Respect to Company's Reportable Segments | Presented below is the financial information with respect to the Company’s reportable segments:
|  | Three Months Ended September 30, |
(in thousands) |  | 2019 |  |  | 2018 |
Revenue: |  |  |  |  |  |  |  |
Therapeutics |  | $ | 4,719 |  |  | $ | 2,115 |
Food |  |  | 146 |  |  |  | 426 |
Total segment revenue |  |  | 4,865 |  |  |  | 2,541 |
Segment operational cash expenditures: |  |  |  |  |  |  |  |
Therapeutics |  | $ | 14,290 |  |  | $ | 11,727 |
Food |  |  | 1,942 |  |  |  | 857 |
Total segment operational cash expenditures |  |  | 16,232 |  |  |  | 12,584 |
Allocation of centralized research and development operational cash expenditures: |  |  |  |  |  |  |  |
Therapeutics |  | $ | 4,081 |  |  | $ | 2,387 |
Food |  |  | — |  |  |  | 597 |
Total allocation of centralized research and development operational cash expenditures |  |  | 4,081 |  |  |  | 2,984 |
Segment operating loss: |  |  |  |  |  |  |  |
Therapeutics |  | $ | (13,652 | ) |  | $ | (11,999 | )
Food |  |  | (1,796 | ) |  |  | (1,028 | )
Total segment operating loss |  |  | (15,448 | ) |  |  | (13,027 | )
Adjustments to reconcile segment operating loss to consolidated loss from operations: |  |  |  |  |  |  |  |
Corporate general and administrative cash expenditures |  | $ | (6,581 | ) |  | $ | (3,719 | )
Interest income received |  |  | (1,236 | ) |  |  | (691 | )
Depreciation and amortization |  |  | (1,401 | ) |  |  | (584 | )
Share-based compensation |  |  | (2,491 | ) |  |  | (292 | )
Changes in prepaid expenses, accounts payable and accrued expenses |  |  | 5,179 |  |  |  | 7,866 |
Total consolidated loss from operations |  | $ | (21,978 | ) |  | $ | (10,447 | )
|  | Nine Months Ended September 30, |
(in thousands) |  | 2019 |  |  | 2018 |
Revenue: |  |  |  |  |  |  |  |
Therapeutics |  | $ | 14,357 |  |  | $ | 5,009 |
Food |  |  | 1,359 |  |  |  | 934 |
Total segment revenue |  |  | 15,716 |  |  |  | 5,943 |
Segment operational cash expenditures: |  |  |  |  |  |  |  |
Therapeutics |  | $ | 42,072 |  |  | $ | 25,903 |
Food |  |  | 6,126 |  |  |  | 2,590 |
Total segment operational cash expenditures |  |  | 48,198 |  |  |  | 28,493 |
Allocation of centralized research and development operational cash expenditures: |  |  |  |  |  |  |  |
Therapeutics |  | $ | 10,952 |  |  | $ | 6,329 |
Food |  |  | — |  |  |  | 1,830 |
Total allocation of centralized research and development operational cash expenditures |  |  | 10,952 |  |  |  | 8,159 |
Segment operating loss: |  |  |  |  |  |  |  |
Therapeutics |  | $ | (38,667 | ) |  | $ | (27,223 | )
Food |  |  | (4,767 | ) |  |  | (3,486 | )
Total segment operating loss |  |  | (43,434 | ) |  |  | (30,709 | )
Adjustments to reconcile segment operating loss to consolidated loss from operations: |  |  |  |  |  |  |  |
Corporate general and administrative cash expenditures |  | $ | (24,726 | ) |  | $ | (8,397 | )
Interest income received |  |  | (3,322 | ) |  |  | (1,213 | )
Depreciation and amortization |  |  | (3,508 | ) |  |  | (1,555 | )
Share-based compensation |  |  | (6,319 | ) |  |  | (697 | )
Loss on disposal of assets |  |  | (22 | ) |  |  | (8 | )
Changes in prepaid expenses, accounts payable and accrued expenses |  |  | 15,988 |  |  |  | 10,772 |
Total consolidated loss from operations |  | $ | (65,343 | ) |  | $ | (31,807 | )

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration